Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OGT Announces the Release of New Genefficiency™ RNA Sequencing Service

Published: Thursday, October 04, 2012
Last Updated: Thursday, October 04, 2012
Bookmark and Share
Turning data into discovery for insightful gene expression analysis.

Oxford Gene Technology (OGT) has announced the release of its new Genefficiency™ RNA Sequencing (RNA-Seq) Service.

Taking advantage of OGT’s experience in optimized sequencing project design and advanced data analysis, this new service overcomes the need for expensive and time-intensive in-house bioinformatics analysis, and has a wide range of other benefits.

To ensure that researchers obtain informative data, OGT provides expert assistance throughout the duration of the project, from the initial stages of experimental design all the way through to the final results.

In addition, the results are presented in an easy-to-use, interactive report that makes the final expression analysis as fast and straightforward as possible.

By taking care of the complexity of sample and data processing, the new service makes RNA-Seq a widely accessible tool for revealing the complexities of the transcriptome.

RNA-Seq allows much broader discoveries at the transcriptome level than many other approaches. It provides the experimental freedom to identify unknown genes and isoforms without having to wait for new versions of exon or custom arrays and genome annotation updates.

Analysis of the data generated allows new information to be revealed, such as changes in transcript activity and variant analysis.

Additional analysis can reveal more in-depth knowledge on alternative splice junctions, allele specific expression and the identification of fusion proteins.

OGT’s Chief Executive Officer, Dr Mike Evans, commented: “Whilst RNA-Seq is a powerful and flexible technology, considerable challenges are presented in terms of the data analysis process. Our optimized pipeline has been specifically designed to help researchers quickly and easily overcome these obstacles, while our purpose-built interactive reporting tool delivers meaningful, accurate publication-ready results for researchers”.

OGT’s intuitive reporting tool allows the quick and effective interrogation of data. The results can be quickly and efficiently examined against a number of parameters, such as differentially expressed genes.

Furthermore, researchers can instantly investigate distinct isoforms for specified genes in order to determine those that are significantly contributing to differential expression at the individual gene-level.

As a comprehensive and fully integrated service, advice and consultation is provided as standard throughout the whole process.

The initial experimental design is fully customizable in order to meet study objectives, with OGT advising on aspects such as the correct combination of starting material and sequencing depth.

Rigorous quality control metrics are used to confirm that reliable, parsimonious, well-mapped reads are informing downstream analysis.

Once the data report is received, a complimentary consultation with an OGT bioinformatician allows the researcher to maximize the potential power of the reporting tool.

In this way, the depth of value provided by the new Genefficiency™ RNA-Seq Service ensures that researchers will quickly generate biological insight from their gene expression research project.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT Announces Commercial and Financial Highlights for FY 2015
New products launched across all core brands; Cytocell® FISH, SureSeq™ NGS and CytoSure™ arrays for cancer and rare disease.
Saturday, December 12, 2015
OGT Licenses SNP Probe Technology to BMGL
Proprietary technology allows superior LOH detection in challenging samples.
Friday, November 13, 2015
OGT’s Popular ESHG Workshop Free to View Online
Learn about the next generation of microarrays in one of the best attended workshops of the conference.
Friday, July 17, 2015
OGT Signs License with Wellcome Trust Sanger Institute
OGT will use novel data on developmental disorders to advance microarray and NGS products for accurate and cost effective identification of rare diseases.
Saturday, April 04, 2015
Oxford Gene Technology Awarded £1.2m Genomics England Contract
Next Generation Sequencing analysis software will support 100,000 Genomes Project by providing intuitive reports for clinical interpretation.
Monday, March 16, 2015
OGT Announces Operational and Financial Highlights for FY 2014
OGT’s molecular genetics business delivers 54% growth in commercial revenues to £11.9m.
Tuesday, December 09, 2014
Pieces of the Puzzle - A Multi-method Approach to Tumour Profiling
OGT workshop provides insight on using complementary genomic technologies.
Friday, November 07, 2014
An Integrated Approach to Clinical Genetics Research
OGT’s new whitepaper explores the next stage of molecular testing.
Wednesday, April 09, 2014
OGT Announces Acquisition of Cytocell Ltd
Company expands leadership in genomic medicine.
Thursday, March 06, 2014
Oxford Gene Technology Expands Leadership in Genomic Medicine
The Company today announced the acquisition of Cambridge-based Cytocell Limited.
Tuesday, March 04, 2014
OGT Strengthens Focus on Cancer Biomarkers
Oxford Gene Technology announce the appointment of Dr Bob Holland as Chief Medical Officer.
Monday, October 21, 2013
OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Awarded Best Medtech Dealmaker by Oxford Bioscience Network
Award recognizes OGT’s collaboration with Birmingham and Salisbury NHS Regional Genetics Laboratories.
Wednesday, October 09, 2013
Exploring the Next Generation of Cancer Genomics at BSGM
aCGH to NGS: OGT invites University of Oxford Professor to present latest research.
Thursday, September 12, 2013
New Whitepaper Compares Targeted Resequencing Strategies
OGT provides insight into choice of NGS methods.
Wednesday, July 17, 2013
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Gene-Editing Improves Vision in Blind Rats
Scientists developed a targeted gene-replacement technique that can modify genes in both dividing and non-dividing cells in living animals.
Gene Editing Yields Tomatoes That Ripen Weeks Earlier
Research team develop method to make tomato plants flower and ripen fruit two weeks faster than current growth rates.
Exploring the Genome of the River Blindness Parasite
Researchers have decoded the genome of the parasite that causes the skin and eye infection known as river blindness.
Unexpected Role for Epigenetic Enzymes in Cancer
Researchers use epigenetics to identify the role of an enzyme family as regulators of genetic message interpretation in yeast.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!